^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
AWT020
i
Other names: AWT020, Mableukin-2PD1, AWT-020, AWT 020
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Anwita Biosci
Drug class:
PD1 inhibitor, IL-2 stimulant
Related drugs:
9ms
Phase 1 Study of AWT020 in Advanced Cancer (clinicaltrials.gov)
P1, N=30, Recruiting, Anwita Biosciences | Phase classification: P1/2 --> P1
Phase classification • Metastases
|
AWT020
1year
Phase 1 Study of AWT020 in Advanced Cancer (clinicaltrials.gov)
P1/2, N=30, Recruiting, Anwita Biosciences
New P1/2 trial • Metastases
|
AWT020
2years
A safe and highly potent PD-1-IL-2 fusion (AWT020) that decouples the efficacy and toxicity of IL-2 therapy (SITC 2022)
Ethics Approval The protocol of animal studies has been reviewed and approved by IACUC. Download figure Open in new tab Download powerpoint Abstract 1104 Figure 1 MOA of AWT020AWT020 is highly specific to tumor infiltrated T cells
Clinical • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IL2RA (Interleukin 2 receptor, alpha) • CD3D (CD3d Molecule) • CXCR3 (C-X-C Motif Chemokine Receptor 3) • CXCR6 (C-X-C Motif Chemokine Receptor 6) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
|
AWT020
Share via
